Promoted Content
Promoted Content

Find Novel Oncology Drugs in Discovery in UNITED STATES

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Small molecule

            Partner/Sponsor/Collaborator: AbbVie Inc

            Deal Size: $1,100.0 million Upfront Cash: $55.0 million

            Deal Type: Collaboration December 02, 2020

            Details:

            Under the multi-year collaboration, AbbVie and Frontier will utilize Frontier's proprietary chemoproteomics platform to identify small molecules for programs directed to novel E3 ligases and certain oncology and immunology targets.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Atbody-st-2

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Large molecule

            Partner/Sponsor/Collaborator: ATB Therapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement December 01, 2020

            Details:

            iBio has entered into its first Statement of Work under a Master Services Agreement with Belgium-based ATB Therapeutics (“atbtherapeutics”) to produce its bioengineered antibody-toxin fusion proteins using iBio’s FastPharming® System.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Takeda Pharmaceutical

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration November 26, 2020

            Details:

            In the course of the strategic research alliance that was announced in June 2020, Egle will validate novel tumor-infiltrating regulatory T-cell (Treg) targets against which Takeda will develop potential therapies.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Bristol-Myers Squibb

            Deal Size: $2,755.0 million Upfront Cash: $55.0 million

            Deal Type: Collaboration November 23, 2020

            Details:

            The collaboration combines Schrödinger’s physics-based computational platform and drug discovery capabilities with BMS's expertise in development and commercialization to advance small molecule therapeutics for targets in oncology, immunology, and neurological disorders.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Small molecule

            Partner/Sponsor/Collaborator: Eli Lilly

            Deal Size: $800.0 million Upfront Cash: $10.0 million

            Deal Type: Collaboration November 13, 2020

            Details:

            The collaboration aims to discover and develop new chemical entities (NCEs) that could produce therapeutic benefit through targeted protein degradation (TPD).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Radioactive labelled-antibodies

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Large molecule

            Partner/Sponsor/Collaborator: AstraZeneca PLC

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration November 02, 2020

            Details:

            The collaboration leverages Fusion’s Targeted Alpha Therapies (TATs) platform and expertise in radiopharmaceuticals with AstraZeneca’s leading portfolio of antibodies and cancer therapeutics, including DNA Damage Response Inhibitors (DDRis).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Small molecule

            Partner/Sponsor/Collaborator: Broad Institute

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership October 22, 2020

            Details:

            The partnership with the Sellers Laboratory at the Broad Institute of MIT and Harvard will utilize the Broad CRISPR paralog screening platform for Synthetic Lethality target and biomarker discovery, including for IDEAYA's PARG program.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 14, 2020

            Details:

            Arvinas is testing two PROTAC® protein degraders in human clinical trials: ARV-110 for the treatment of men with metastatic castrate-resistant prostate cancer and ARV-471 for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Small molecule

            Partner/Sponsor/Collaborator: Casdin Capital

            Deal Size: $57.6 million Upfront Cash: Undisclosed

            Deal Type: Series B Financing October 13, 2020

            Details:

            Proceeds from this financing will support ongoing efforts to build a broad portfolio of small molecule medicines, including the identification and preclinical development of Cedilla’s first two product candidates.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): CAR-T cell therapy

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Neogene

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership October 13, 2020

            Details:

            The companies will leverage Neogene’s expertise in targeting tumor neo-antigens, mutated proteins found in cancer cells together with Twist’s DNA synthesis platform and product lines to develop personalized CAR) T cell therapies and TCR therapies for patients with cancer.

            PharmaCompass